QUARTA, SANTINA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.963
AS - Asia 4.550
EU - Europa 2.018
SA - Sud America 787
AF - Africa 628
Continente sconosciuto - Info sul continente non disponibili 68
OC - Oceania 66
Totale 15.080
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.584
SG - Singapore 1.390
CN - Cina 862
VN - Vietnam 744
HK - Hong Kong 532
BR - Brasile 512
IT - Italia 439
DE - Germania 232
FI - Finlandia 188
SE - Svezia 155
IN - India 137
FR - Francia 136
BD - Bangladesh 129
PL - Polonia 123
GB - Regno Unito 96
CA - Canada 75
NL - Olanda 69
RU - Federazione Russa 64
AR - Argentina 56
IQ - Iraq 55
MX - Messico 54
JP - Giappone 51
TR - Turchia 50
UA - Ucraina 49
PH - Filippine 45
PK - Pakistan 43
AT - Austria 41
ZA - Sudafrica 40
MA - Marocco 36
EC - Ecuador 34
UZ - Uzbekistan 33
CO - Colombia 32
ES - Italia 32
IE - Irlanda 32
KR - Corea 32
ID - Indonesia 31
JO - Giordania 31
JM - Giamaica 28
PE - Perù 28
PY - Paraguay 28
VE - Venezuela 28
AE - Emirati Arabi Uniti 26
LY - Libia 24
MN - Mongolia 24
MY - Malesia 24
SA - Arabia Saudita 24
CL - Cile 23
NI - Nicaragua 23
AO - Angola 22
CY - Cipro 22
TH - Thailandia 22
CH - Svizzera 21
CR - Costa Rica 21
AL - Albania 20
AZ - Azerbaigian 20
BF - Burkina Faso 20
KZ - Kazakistan 20
AU - Australia 19
BB - Barbados 19
CI - Costa d'Avorio 19
CM - Camerun 19
IR - Iran 19
PA - Panama 19
BE - Belgio 18
BO - Bolivia 18
CZ - Repubblica Ceca 18
ET - Etiopia 18
KG - Kirghizistan 18
LB - Libano 18
LC - Santa Lucia 18
UY - Uruguay 18
DZ - Algeria 17
EG - Egitto 17
GH - Ghana 17
IS - Islanda 17
SD - Sudan 17
TW - Taiwan 17
BZ - Belize 16
GR - Grecia 16
LA - Repubblica Popolare Democratica del Laos 16
LV - Lettonia 16
ML - Mali 16
RO - Romania 16
SN - Senegal 16
CG - Congo 15
DJ - Gibuti 15
GN - Guinea 15
NE - Niger 15
SK - Slovacchia (Repubblica Slovacca) 15
TZ - Tanzania 15
AD - Andorra 14
BJ - Benin 14
GT - Guatemala 14
HR - Croazia 14
HU - Ungheria 14
MG - Madagascar 14
NZ - Nuova Zelanda 14
PS - Palestinian Territory 14
PT - Portogallo 14
SO - Somalia 14
Totale 14.414
Salva come PNG Salva come JPEG
Città #
Singapore 874
San Jose 790
Ashburn 741
Fairfield 502
Hong Kong 476
Chandler 418
Woodbridge 285
Houston 250
Jacksonville 233
Wilmington 231
Ann Arbor 220
Ho Chi Minh City 215
Santa Clara 214
Cambridge 197
Los Angeles 195
Seattle 191
Hanoi 184
Beijing 152
Boardman 136
Padova 105
Bytom 89
Helsinki 89
New York 86
Princeton 79
Lauterbourg 74
Des Moines 73
Munich 69
San Diego 66
Nanjing 65
Medford 57
Council Bluffs 48
São Paulo 48
Da Nang 41
Dearborn 40
Chicago 39
Hefei 39
Buffalo 38
Guangzhou 38
Roxbury 35
Turku 35
Frankfurt am Main 33
London 33
Orem 32
Tashkent 31
Tokyo 31
Amman 30
Haiphong 30
Rome 28
Brooklyn 27
Dallas 27
Milan 27
Nuremberg 27
Dublin 26
Johannesburg 26
Padua 26
Shenyang 25
Warsaw 25
Atlanta 24
Montreal 24
Changsha 23
Ulan Bator 22
Phoenix 21
Pune 21
Stockholm 21
Amsterdam 20
Baku 20
Lima 20
Managua 20
The Dalles 20
Abidjan 19
Luanda 19
Vienna 19
Denver 18
Panama City 18
Baghdad 17
Chennai 17
Boston 16
Castries 16
Dakar 16
Kingston 16
Riga 16
Shanghai 16
Accra 15
Addis Ababa 15
Bamako 15
Bishkek 15
Dong Ket 15
Jinan 15
Lahore 15
Rio de Janeiro 15
San Francisco 15
Tianjin 15
Tripoli 15
Andorra la Vella 14
Antananarivo 14
Biên Hòa 14
Bridgetown 14
Detroit 14
Istanbul 14
Jiaxing 14
Totale 8.983
Salva come PNG Salva come JPEG
Nome #
Binding and Uptake into Human Hepatocellular Carcinoma Cells of Peptide-Functionalized Gold Nanoparticles 388
PreS1 peptide-functionalized gold nanostructures with SERRS tags for efficient liver cancer cell targeting 359
1-Piperidine Propionic Acid Protects from Septic Shock Through Protease Receptor 2 Inhibition 349
SCCA1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity 319
Low p66shc with high serpinb3 levels favors necroptosis and better survival in hepatocellular carcinoma 303
Synthesis, chemical characterization and cancer cell growth-inhibitory activities of Cu(ii) and Ru(iii) aliphatic and aromatic dithiocarbamato complexes 285
Au(III)-Proline derivatives exhibiting selective antiproliferative activity against HepG2/SB3 apoptosis-resistant cancer cells 276
SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity 276
Biological and clinical implications of HBV infection in peripheral blood mononuclear cells 270
SerpinB3/Protease Activated Receptor-2 Axis Is Essential for SARS CoV-2 Infection 265
SERPINB3 induces epithelial-mesenchymal transition. 263
SerpinB3 induces dipeptidyl-peptidase IV/CD26 expression and its metabolic effects in hepatocellular carcinoma 250
Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells. 242
Squamous cell carcinoma antigen (SCCA) is up-regulated during Barrett's carcinogenesis and predicts esophageal adenocarcinoma resistance to neoadjuvant chemotherapy 241
Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis 239
The Protease Activated Receptor 2 - CCAAT/Enhancer-Binding Protein beta - SerpinB3 axis inhibition as a novel strategy for the treatment of Non-Alcoholic Steatohepatitis 237
MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma 236
SERPINB3 INDUCES EPITHELIAL MESENCHYMAL TRANSITION 234
Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma 227
SERPINB3, apoptosis and autoimmunity 226
Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease 225
1-Piperidine Propionic Acid as an Allosteric Inhibitor of Protease Activated Receptor-2 224
SERPINB3 AS A PRO-INFLAMMATORY MEDIATOR IN THE PROGRESSION OF EXPERIMENTAL NON-ALCOHOLIC FATTY LIVER DISEASE. 221
Hepatic progenitor cells express SerpinB3 220
Biodistribution of Intratracheal, Intranasal, and Intravenous Injections of Human Mesenchymal Stromal Cell-Derived Extracellular Vesicles in a Mouse Model for Drug Delivery Studies 214
Exogenous Administration of SERPINB3 Inhibits Cell Reprogramming 214
Role of squamous cell carcinoma antigen-1 on liver cells after partial hepatectomy in transgenic mice. 214
Re-programming pullulan for targeting and controlled release of doxorubicin to the hepatocellular carcinoma cells 211
SerpinB3 promotes pro-fibrogenic responses in activated hepatic stellate cells 210
Over-expression of SERPINB3 in hepatoblastoma: A possible insight into the genesis of this tumour? 207
Labelled micelles for the delivery of cytotoxic Cu(II) and Ru(III) compounds in the treatment of aggressive orphan cancers: design and biological in vitro data 205
SerpinB3 administration protects liver against ischemia-reperfusion injury 203
Epitope-Specific Anti-SerpinB3 Antibodies for SerpinB3 Recognition and Biological Activity Inhibition 203
Semisolid Wet Sol–Gel Silica/Hydroxypropyl Methyl Cellulose Formulation for Slow Release of Serpin B3 Promotes Wound Healing In Vivo 200
CARATTERIZZAZIONE BIOLOGICA E FUNZIONE DELLA NUOVA ISOFORMA SCCA-PD 197
SerpinB3 Upregulates Low-Density Lipoprotein Receptor-Related Protein (LRP) Family Members, Leading to Wnt Signaling Activation and Increased Cell Survival and Invasiveness 196
The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma 194
Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis 184
Deregulation of Squamous Cell Carcinoma Antigen (SCCA) expression in B lymphocytes in patients with chronic hepatitis C 183
HEPATIC PROGENITOR CELLS OVEREXPRESS SERPINB3 IN A MOUSE MODEL OF FULMINANT HEPATITIS 181
HFE, TGF-BETA1 AND SQUAMOUS CELL CARCNOMA ANTIGEN-1 POLYMORPHISMS AND LIVER DISEASE STAGE IN CHRONIC HCV INFECTION 175
The polymorphic variant of SerpinB3 (SerpinB3-PD) is associated with faster cirrhosis decompensation 173
Vescicole extracellulari da cellule geneticamente modificate iperesprimenti SerpinB3 per uso come agenti terapeutici 167
Circulating Squamous Cell Carcinoma Antigen-IgM complexes as novel biomarkers for hepatocellular carcinoma 163
Activation of pivotal cell cycle proteins and inhibition of apoptosis by SCCA1 in HepG2 cells 162
Monitoring SCCA-IgM complex predicts liver disease progression in patients with chronic hepatitis and cirrhosis 160
POLIMORFISMO DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) E PROGRESSIONE DELLA MALATTIA EPATICA NELL’INFEZIOE HCV 159
RUOLO DI SERPINB3 ELLA PROGRESSIONE DELLA MALATTIA EPATICA 156
SCCA EXPRESSION IN PBMCs IN PATIENTS WITH CHRONIC HEPATITIS C 156
SERPINB3 modulates TGF-beta expression in chronic liver disease. 155
SERPINB3 INDUCES EPITHELIAL MESENCHYMAL TRANSITION 150
ESPRESSIONE DELLA SERPINA SCCA IN CELLULE MONONUCLEATE DI SANGUE PERIFERICO IN PAZIENTI CO INFEZIONE CRONICA DA HCV 148
DEREGOLAZIONE DELL’ESPRESSIONE DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) NEI LINFOCITI B IN PAZIENTI INFETTI DA HCV 147
CHARACTERIZATION OF SCCA-1(SERPINB3) ISOFORMS IN HEPATOCELLULAR CARCINOMA 144
Espressione della serpina SCCA in cellule mononucleate di sangue periferico in pazienti con infezione cronica da HCV 142
Inhibition of Protease-Activated Receptor-2 Activation in Parkinson’s Disease Using 1-Piperidin Propionic Acid 141
DOWNREGULATION OF SURFACE SQUAMOUS CELL CARCINOMA ANTIGEN EXPRESSION AND CD27+ MOLECULE ON B LYMPHOCYTES IN PATIENTS WITH CHRONIC HEPATITIS C 141
SQUAMOUS CELL CARCINOMA ANTIGEN (SCCA) ENHANCES LIVER REGENERATION AFTER PARTIAL HEPATECTOMY 141
SCCA overexpression induces cell proliferation and down-regulation of the adhesion system 139
HPYPOXYA UP-REGULATES SERPINB3 IN HEPATIC CANCER CELLS: A HIF-2a ASSOCIATED EVENT RELATED TO INVASIVENESS AND EPITHELIAL TO MESENCHYMAL TRANSITION 138
OVEREXPRESSION OF SERPINB3 IN HEPATIC PROGENITOR CELLS IN A MOUSE MODEL OF ACUTE LIVER INJURY 138
COMPORTAMENTO DI SCCA-IgM NEL SIERO DI BAMBINI HBeAg POSITIVI SEGUITI NEL TEMPO 136
HYPOXIA UP-REGULATES SERPINB3 IN HEPG2 CELLS: A REDOX SENSITIVE EVENT RELATED TOEPITHELIAL TO MESENCHYMAL TRANSITIONAND INVASIVENESS 135
HCC invasiveness induced by SCCA is associated with nuclear beta-catenin accumulation 132
A New Assay for Quantitative Determination of Pres1-Encoded Protein in Patients Infected with Hepatitis B and Delta Viruses 131
Squamous cell carcinoma antigen (SCCA) expression and CD27+ memory B lymphocytes in patients with chronic hepatitis C and systemic lupus erythematosus (SLE) 131
SERPINB3 PROMUOVE L’INVASIVITA’ CELLULARE 128
SCCA1-IGM AND SCCA2-IGM COMPARED WITH TOTAL SCCA-IGM FOR DIAGNOSIS OF HEPATOCELLULAR CARCINOMA 125
ESPRESSIONE DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) E CELLULE B DELLA MEMORIA IN CORSO DI INFEZIONE DA VIRUS DELL’EPATITE C 125
PRO-ONCOGENIC EFFECT OF SQUAMOUS CELL CARCINOMA ANTIGEN VIA WNT/BETA-CATENIN SIGNALING 122
ESPRESSIONE DI TGF-b1 NELLA MALATTIA EPATICA EVOLUTIVA 115
SERPINB3 AND TGF-BETA IN CHRONIC LIVER DISEASE 115
Serum SCCA IgM complexes increase over time and HCC development in cirrhotic patients 110
SEX DEPENDENT IL-6 DEREGULATION BY SERPINB3 IN A TRANSGENIC MOUSE MODEL 108
CELLULE PROGENITRICI EPATICHE ESPRIMONO SERPINB3 IN UN MODELLO MURINO DI EPATITE FULMINANTE 106
SERPINB3 AND TGF-BETA1 CORRELATION IN CHRONIC LIVER DISEASE OF VIRAL ETIOLOGY 102
SERPINB3 UP-REGULATION BY HYPOXIA IN HEPG2 CELLS : A HIF-2ALPHA AND REDOX SENSITIVE EVENT RELATED TO INVASIVENESS AND EPITHELIAL TO MESENCHYMAL TRANSITION 101
The impact of serpinB3-PD polymorphism on the prognosis of patients with hepatocellular carcinoma 97
MODULAZIONE DEI LIVELLI DI IL-6 NELLA RIGENERAZIONE EPATICA DA PARTE DI SERPINB3 ED ESTROGENI. ANALISI IN UN MODELLO DI TOPO TRANSGENICO 97
SERPINB3 AND TGF-BETA1 CORRELATION IN CHRONIC LIVER DISEASE 90
Hepatotropic viruses: new insights in pathogenesis and treatment 88
Totale 15.080
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.873
article - articoli 34.005
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 435
selected - selezionate 0
volume - volumi 0
Totale 76.313
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022692 0 103 79 58 27 47 32 64 33 9 81 159
2022/2023885 140 88 18 96 153 146 0 79 107 6 38 14
2023/2024457 14 65 67 29 49 67 39 17 10 18 35 47
2024/20252.104 10 202 75 99 212 67 89 130 152 99 413 556
2025/20267.942 402 676 970 1.001 819 354 1.417 644 769 421 280 189
2026/2027364 299 65 0 0 0 0 0 0 0 0 0 0
Totale 15.080